What is Hologic Inc's earnings per share (EPS)?

Hologic Inc (HOLX) reported diluted earnings per share of $2.49 for fiscal year 2025. This represents a -25.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hologic Inc (HOLX) Financials

HOLX

Trailing 12 months to December 27, 2025

Revenue $4.1B +2.2% YoY

Net Income $543.8M -26.9% YoY

EPS (Diluted) $2.40 -24.1% YoY

Free Cash Flow $994.1M -14.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Dec 27, 2025 Reported Jan 29, 2026 Currency USD FYE September

Newest figures come from the 10-Q for Q1 FY2026, filed Jan 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HOLX SEC filings page.

Hologic Inc (HOLX) reported $4.1B in revenue over the twelve months to Dec 27, 2025, up 2.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HOLX FY2025 2026-10-03

Hologic's recovery remains profitable but uneven: 2025 revenue held steady while margins, cash generation, and returns retreated from FY2024.

The near-flat top line did not translate into earnings: operating margin fell from 21.9% to 17.4%, indicating weaker operating economics rather than a volume-driven acceleration. Operating cash flow also declined from $1.29B to $1.06B, so the 2025 profit recovery was less cash-supported than the prior year's improvement.

The balance sheet is less pressured by short-term obligations: current ratio remained near 3.8x in FY2025, while total liabilities were below FY2024's level despite long-term debt remaining broadly stable. That combination points to balance-sheet improvement coming mainly from lower non-debt obligations, not substantial deleveraging.

Cash conversion remained favorable: FY2025 free cash flow of $998M exceeded net income of $566M, though the cash yield was weaker than in FY2024. Buybacks of $753M consumed most of that year's free cash flow, while capital spending was only $59M, making shareholder returns the larger use of internally generated cash.

Financial Health Signals

Financial Health Score 69/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Hologic Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Hologic Inc has an operating margin of 17.4%, meaning the company retains $17 of operating profit per $100 of revenue. This strong profitability earns a score of 79/100, reflecting efficient cost management and pricing power. This is down from 21.9% the prior year.

Growth

Hologic Inc's revenue grew a modest 1.7% year-over-year to $4.1B. This slow but positive growth earns a score of 33/100.

Leverage

Hologic Inc has a moderate D/E ratio of 0.50. This balance of debt and equity financing earns a leverage score of 59/100.

Liquidity

With a current ratio of 3.75, Hologic Inc holds $3.75 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 86/100.

Cash Flow

Hologic Inc converts 24.3% of revenue into free cash flow ($998.3M). This strong cash generation earns a score of 92/100.

Returns

Hologic Inc's ROE of 11.2% shows moderate profitability relative to equity, earning a score of 63/100. This is down from 15.4% the prior year.

Altman Z-Score Safe

4.17

Hologic Inc scores 4.17, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($17.0B) relative to total liabilities ($4.0B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

Hologic Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.87x

For every $1 of reported earnings, Hologic Inc generates $1.87 in operating cash flow ($1.1B OCF vs $565.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

6.10x

Hologic Inc earns $6.10 in operating income for every $1 of interest expense ($714.3M vs $117.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.0B

YoY+2.5%

QoQ-0.2%

5Y CAGR-4.9%

10Y CAGR+4.2%

Hologic Inc generated $1.0B in revenue in Q1 2026. This represents an increase of 2.5% from the same quarter a year earlier. Against the prior quarter it is down 0.2%.

EBITDA

$306.6M

YoY+0.9%

QoQ-3.1%

Hologic Inc's EBITDA was $306.6M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.9% from the same quarter a year earlier. Against the prior quarter it is down 3.1%.

Net Income

$179.1M

YoY-10.9%

QoQ-4.3%

5Y CAGR-18.3%

10Y CAGR+19.8%

Hologic Inc reported $179.1M in net income in Q1 2026. This represents a decrease of 10.9% from the same quarter a year earlier. Against the prior quarter it is down 4.3%.

EPS (Diluted)

$0.79

YoY-9.2%

QoQ-4.8%

5Y CAGR-15.9%

10Y CAGR+23.0%

Hologic Inc earned $0.79 per diluted share (EPS) in Q1 2026. This represents a decrease of 9.2% from the same quarter a year earlier. Against the prior quarter it is down 4.8%.

Cash & Balance Sheet

Free Cash Flow

$215.2M

YoY+24.8%

QoQ-37.0%

5Y CAGR-11.5%

10Y CAGR-0.4%

Hologic Inc generated $215.2M in free cash flow in Q1 2026, representing cash available after capex. This represents an increase of 24.8% from the same quarter a year earlier. Against the prior quarter it is down 37.0%.

Cash & Debt

$2.2B

YoY+21.7%

QoQ+10.6%

5Y CAGR+25.3%

10Y CAGR+9.4%

Hologic Inc held $2.2B in cash against $2.5B in long-term debt as of Q1 2026.

Shares Outstanding

223M

YoY-0.5%

QoQ+0.2%

5Y CAGR-2.8%

10Y CAGR-2.3%

Hologic Inc had 223M shares outstanding in Q1 2026. This represents a decrease of 0.5% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

56.0%

YoY-0.9pp

QoQ+0.4pp

5Y change-13.2pp

10Y change+1.4pp

Hologic Inc's gross margin was 56.0% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.4 percentage points.

Operating Margin

22.6%

YoY+0.1pp

QoQ+0.1pp

Hologic Inc's operating margin was 22.6% in Q1 2026, reflecting core business profitability. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.

Net Margin

17.1%

YoY-2.6pp

QoQ-0.8pp

5Y change-19.6pp

10Y change+12.8pp

Hologic Inc's net profit margin was 17.1% in Q1 2026, showing the share of revenue converted to profit. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.

Return on Equity

3.4%

YoY-0.8pp

QoQ-0.3pp

5Y change-14.8pp

10Y change+2.1pp

Hologic Inc's ROE was 3.4% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.

Capital Allocation

R&D Spending

$60.5M

YoY+0.3%

QoQ-6.9%

Hologic Inc invested $60.5M in research and development in Q1 2026. This represents an increase of 0.3% from the same quarter a year earlier. Against the prior quarter it is down 6.9%.

Share Buybacks

YoY-100.0%

Hologic Inc repurchased no shares in Q1 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Capital Expenditures

$14.7M

YoY-12.5%

QoQ+7.3%

5Y CAGR-20.1%

10Y CAGR-2.2%

Hologic Inc invested $14.7M in capex in Q1 2026, funding long-term assets and infrastructure. This represents a decrease of 12.5% from the same quarter a year earlier. Against the prior quarter it is up 7.3%.

HOLX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HOLX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$4.1B	$4.1B+1.7%	$4.0B0.0%	$4.0B-17.1%	$4.9B-13.7%	$5.6B+49.1%	$3.8B+12.1%	$3.4B+4.6%	$3.2B+5.2%	$3.1B+8.0%	$2.8B+4.7%	$2.7B+6.9%	$2.5B+1.5%	$2.5B+24.5%	$2.0B+11.9%	$1.8B
Cost of Revenue	N/A	$1.6B+1.8%	$1.6B+1.4%	$1.5B	N/A	N/A	N/A	N/A	$886.6M+0.5%	$881.8M+16.5%	$756.8M+0.2%	$755.5M+3.3%	$731.3M-10.6%	$818.2M+32.7%	$616.8M+18.3%	$521.2M
Gross Profit	$2.1B	$2.1B-4.9%	$2.2B+7.5%	$2.1B-30.9%	$3.0B-21.0%	$3.8B+70.4%	$2.2B+90.2%	$1.2B-31.0%	$1.7B+4.7%	$1.6B+3.7%	$1.6B+9.1%	$1.4B+15.0%	$1.2B+7.2%	$1.2B+16.8%	$994.4M-21.6%	$1.3B
R&D Expenses	$248.4M	$248.2M-9.0%	$272.8M-7.3%	$294.3M+3.8%	$283.4M+2.6%	$276.3M+24.2%	$222.5M-4.2%	$232.2M+6.2%	$218.7M-6.1%	$232.8M+0.3%	$232.1M+8.0%	$214.9M+5.8%	$203.2M+2.8%	$197.6M+50.8%	$131.0M+12.3%	$116.7M
SG&A Expenses	$461.4M	$449.3M+9.7%	$409.4M+4.3%	$392.4M-3.8%	$407.7M-5.9%	$433.2M+21.8%	$355.7M+7.0%	$332.3M-9.2%	$366.1M+6.6%	$343.3M+28.4%	$267.3M+2.4%	$261.0M+0.5%	$259.8M+14.1%	$227.7M+3.3%	$220.5M+38.2%	$159.6M
Operating Income	$721.5M	$714.3M-19.1%	$882.6M+32.0%	$668.4M-59.2%	$1.6B-33.9%	$2.5B+124.5%	$1.1B+992.6%	-$123.8M+48.0%	-$237.9M-117.4%	$1.4B+149.8%	$548.6M+20.5%	$455.1M+62.7%	$279.7M+130.9%	-$906.2M-897.0%	$113.7M-69.6%	$374.4M
EBITDA	N/A	$1.0B-14.9%	$1.2B+20.1%	$991.8M-52.1%	$2.1B-28.3%	$2.9B+94.9%	$1.5B+336.5%	$339.3M+40.0%	$242.4M-86.7%	$1.8B+79.4%	$1.0B+7.1%	$946.5M+17.9%	$802.9M+305.8%	-$390.2M-184.9%	$459.5M-32.3%	$679.2M
Interest Expense	$114.2M	$117.1M-4.1%	$122.1M+9.9%	$111.1M+16.8%	$95.1M+1.6%	$93.6M-19.7%	$116.5M-17.3%	$140.8M-5.3%	$148.7M-2.9%	$153.2M-1.4%	$155.3M-24.4%	$205.5M-6.8%	$220.6M-21.5%	$281.1M+100.4%	$140.3M+22.2%	$114.8M
Income Tax	$119.6M	$115.5M+52.8%	$75.6M-65.7%	$220.1M-23.1%	$286.2M-41.8%	$491.4M+552.5%	-$108.6M-100.7%	-$54.1M+82.4%	-$307.3M-164.7%	$475.0M+462.1%	$84.5M+85.3%	$45.6M+48.1%	$30.8M+253.2%	-$20.1M-268.9%	$11.9M-83.1%	$70.2M
Net Income	$543.8M	$565.7M-28.3%	$789.5M+73.1%	$456.0M-65.0%	$1.3B-30.4%	$1.9B+67.8%	$1.1B+647.7%	-$203.6M-82.9%	-$111.3M-114.7%	$755.5M+128.4%	$330.8M+151.4%	$131.6M+660.7%	$17.3M+101.5%	-$1.2B-1493.5%	-$73.6M-146.8%	$157.2M
EPS (Basic)	N/A	$2.50-25.4%	$3.35+81.1%	$1.85-64.3%	$5.18-28.8%	$7.28+71.7%	$4.24+657.9%	-$0.76-90.0%	-$0.40-114.8%	$2.70+128.8%	$1.18+151.1%	$0.47+683.3%	$0.06+101.4%	-$4.36-1457.1%	-$0.28-146.7%	$0.60
EPS (Diluted)	$2.40	$2.49-25.0%	$3.32+81.4%	$1.83-64.3%	$5.13-28.8%	$7.21+71.3%	$4.21+653.9%	-$0.76-90.0%	-$0.40-115.2%	$2.64+127.6%	$1.16+157.8%	$0.45+650.0%	$0.06+101.4%	-$4.36-1457.1%	-$0.28-147.5%	$0.59
Diluted Shares (Avg)	N/A	228M-4.2%	238M-4.5%	249M-2.0%	254M-2.3%	260M-1.9%	265M-1.8%	269M-2.1%	275M-3.7%	286M-0.2%	286M-1.2%	290M+4.0%	278M+3.6%	269M+1.8%	264M-0.1%	264M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Revenue	$1.0B+2.5%	$1.0B+6.2%	$1.0B+1.2%	$1.0B-1.2%	$1.0B+0.9%	$988.0M+0.4%	$1.0B-1.5%	$1.0B
Cost of Revenue	$417.6M+6.5%	N/A	N/A	N/A	$392.0M+27.6%	N/A	N/A	$308.6M
Gross Profit	$586.4M+1.0%	$583.5M+4.6%	$576.6M+2.9%	$377.3M-30.4%	$580.5M+2.3%	$557.7M+51.8%	$560.3M-4.4%	$542.3M
R&D Expenses	$60.5M+0.3%	$65.0M-3.4%	$61.4M-4.2%	$61.5M-17.6%	$60.3M-9.7%	$67.3M-7.3%	$64.1M-13.4%	$74.6M
SG&A Expenses	$127.8M+10.5%	$114.8M+11.2%	$99.1M+5.4%	$119.7M+19.2%	$115.7M+3.5%	$103.2M+14.4%	$94.0M-6.7%	$100.4M
Operating Income	$237.0M+3.1%	$236.9M+3.0%	$254.6M+4.3%	-$7.0M-103.3%	$229.8M+15.9%	$230.0M+16328.6%	$244.0M-10.3%	$210.4M
EBITDA	$306.6M+0.9%	$316.3M+3.8%	$324.8M+2.7%	$69.2M-75.6%	$303.8M+6.0%	$304.6M+268.8%	$316.3M-10.4%	$284.1M
Interest Expense	$27.6M-9.5%	$28.6M-10.3%	$28.9M-9.4%	$29.1M-9.9%	$30.5M+17.3%	$31.9M+15.2%	$31.9M+17.3%	$32.3M
Income Tax	$50.6M+8.8%	$40.0M-7.0%	$40.1M-13.2%	-$11.1M-126.7%	$46.5M+184.2%	$43.0M-18.3%	$46.2M-24.0%	$41.6M
Net Income	$179.1M-10.9%	$187.2M+4.8%	$194.9M+0.2%	-$17.4M-110.2%	$201.0M-18.5%	$178.6M+541.0%	$194.5M-11.0%	$169.9M
EPS (Basic)	$0.80-8.0%	$0.83+7.8%	$0.87+4.8%	-$0.08-111.1%	$0.87-15.5%	$0.77+581.3%	$0.83-5.7%	$0.72
EPS (Diluted)	$0.79-9.2%	$0.83+10.7%	$0.86+4.9%	-$0.08-111.1%	$0.87-15.5%	$0.75+568.8%	$0.82-5.7%	$0.72
Diluted Shares (Avg)	226M-2.7%	N/A	225M-4.7%	226M-5.0%	232M-3.4%	N/A	236M-5.3%	238M

HOLX Balance Sheet

HOLX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$9.0B-1.5%	$9.2B+0.2%	$9.1B+0.8%	$9.1B+1.7%	$8.9B+24.0%	$7.2B+11.7%	$6.4B-10.9%	$7.2B-9.4%	$8.0B+9.1%	$7.3B-4.3%	$7.6B-8.7%	$8.4B-7.0%	$9.0B-14.1%	$10.5B+74.4%	$6.0B
Current Assets	$3.7B-4.1%	$3.8B-8.6%	$4.2B+8.4%	$3.9B+21.9%	$3.2B+42.6%	$2.2B+23.9%	$1.8B+4.1%	$1.7B+16.5%	$1.5B+11.5%	$1.3B+4.8%	$1.3B-19.2%	$1.6B-3.6%	$1.6B+3.9%	$1.6B+16.4%	$1.3B
Cash & Equivalents	$2.0B-9.3%	$2.2B-20.7%	$2.7B+16.4%	$2.3B+99.9%	$1.2B+66.9%	$701.0M+16.5%	$601.8M-9.7%	$666.7M+23.3%	$540.6M-1.4%	$548.4M+11.6%	$491.3M-33.3%	$736.1M-10.5%	$822.5M+46.8%	$560.4M-21.3%	$712.3M
Short-Term Investments	$243.2M+40.3%	$173.4M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$679.4M-0.1%	$679.8M+10.1%	$617.6M-1.0%	$623.7M+24.4%	$501.2M+26.9%	$395.1M-11.2%	$444.9M+15.8%	$384.1M+15.8%	$331.6M+20.7%	$274.7M-3.0%	$283.1M-14.4%	$330.6M+14.2%	$289.4M-21.2%	$367.2M+59.3%	$230.5M
Accounts Receivable	$600.8M+0.1%	$600.4M-4.0%	$625.6M+1.3%	$617.6M-34.5%	$942.7M-8.4%	$1.0B+58.6%	$648.7M+12.0%	$579.2M+8.6%	$533.5M+19.4%	$447.0M+7.4%	$416.1M+5.1%	$396.0M-3.2%	$409.3M0.0%	$409.3M+28.4%	$318.7M
Long-Term Investments	$0-100.0%	$96.4M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$3.6B+5.7%	$3.4B+4.9%	$3.3B+1.4%	$3.2B-1.4%	$3.3B+23.5%	$2.7B+3.7%	$2.6B+1.2%	$2.5B-20.1%	$3.2B+13.1%	$2.8B-0.2%	$2.8B-0.1%	$2.8B-0.1%	$2.8B-28.6%	$3.9B+72.1%	$2.3B
Total Liabilities	$4.0B-1.5%	$4.0B-2.3%	$4.1B-1.7%	$4.2B-10.8%	$4.7B+4.7%	$4.5B+3.8%	$4.3B-9.9%	$4.8B-7.6%	$5.2B+0.4%	$5.2B-7.0%	$5.6B-11.8%	$6.3B-10.7%	$7.1B-6.1%	$7.5B+144.7%	$3.1B
Current Liabilities	$977.2M-5.8%	$1.0B-14.1%	$1.2B+28.8%	$937.7M-29.3%	$1.3B+7.1%	$1.2B+15.8%	$1.1B-23.7%	$1.4B-24.8%	$1.9B+106.8%	$901.9M-4.4%	$943.4M+52.3%	$619.6M-43.1%	$1.1B+64.6%	$661.3M+29.8%	$509.4M
Non-Current Liabilities	$3.0B0.0%	$3.0B+2.5%	$2.9B-10.5%	$3.3B-3.5%	$3.4B+3.8%	$3.3B-0.2%	$3.3B-4.2%	$3.4B+2.1%	$3.3B-22.1%	$4.3B-7.5%	$4.6B-18.8%	$5.7B-4.8%	$6.0B-12.9%	$6.9B+167.5%	$2.6B
Long-Term Debt	$2.5B+0.3%	$2.5B-1.3%	$2.5B-9.9%	$2.8B+3.5%	$2.7B-0.1%	$2.7B-2.5%	$2.8B+2.9%	$2.7B+24.5%	$2.2B-28.8%	$3.0B-5.3%	$3.2B-22.4%	$4.2B-2.1%	$4.2B-14.7%	$5.0B+234.0%	$1.5B
Total Equity	$5.0B-1.6%	$5.1B+2.3%	$5.0B+2.9%	$4.9B+15.6%	$4.2B+55.9%	$2.7B+27.9%	$2.1B-12.9%	$2.4B-12.8%	$2.8B+30.0%	$2.1B+3.1%	$2.1B+0.8%	$2.1B+6.3%	$1.9B-34.4%	$3.0B+0.8%	$2.9B
Retained Earnings	$3.4B+19.9%	$2.8B+38.4%	$2.1B+28.5%	$1.6B+436.5%	$298.3M+119.0%	-$1.6B+41.5%	-$2.7B-7.8%	-$2.5B-4.7%	-$2.4B+24.1%	-$3.1B+9.5%	-$3.5B+3.7%	-$3.6B+0.4%	-$3.6B-48.0%	-$2.4B-3.1%	-$2.4B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Total Assets	$9.2B+5.2%	$9.0B-1.5%	$8.8B-0.9%	$8.5B-1.9%	$8.7B+3.1%	$9.2B-1.9%	$8.9B-5.9%	$8.7B
Current Assets	$3.8B+10.0%	$3.7B-4.1%	$3.4B-14.4%	$3.2B-15.3%	$3.5B0.0%	$3.8B-11.9%	$4.0B-5.1%	$3.8B
Cash & Equivalents	$2.2B+21.7%	$2.0B-9.3%	$1.7B-28.9%	$1.4B-34.4%	$1.8B-7.8%	$2.2B-21.9%	$2.4B-5.5%	$2.2B
Short-Term Investments	$196.7M+3.2%	$243.2M+40.3%	$143.9M	$191.5M	$190.6M	$173.4M	$0	$0
Inventory	$688.5M-2.6%	$679.4M-0.1%	$713.7M+7.2%	$716.7M+10.4%	$707.1M+11.6%	$679.8M0.0%	$665.5M-3.2%	$649.2M
Accounts Receivable	$584.2M-7.5%	$600.8M+0.1%	$609.3M-3.1%	$644.4M-0.4%	$631.4M-5.9%	$600.4M-12.6%	$628.5M-12.0%	$647.1M
Long-Term Investments	$0-100.0%	$0-100.0%	$0	$0	$47.9M	$96.4M	$0	$0
Goodwill	$3.6B+6.5%	$3.6B+5.7%	$3.6B+10.7%	$3.6B+10.1%	$3.4B+3.5%	$3.4B+4.4%	$3.3B-0.2%	$3.3B
Total Liabilities	$3.9B-0.5%	$4.0B-1.5%	$4.0B+0.6%	$3.9B+1.5%	$4.0B+3.7%	$4.0B-3.1%	$3.9B-5.0%	$3.9B
Current Liabilities	$951.3M-5.1%	$977.2M-5.8%	$962.5M-4.0%	$989.7M+3.7%	$1.0B+11.5%	$1.0B+5.7%	$1.0B+5.0%	$954.6M
Non-Current Liabilities	$3.0B+1.1%	$3.0B0.0%	$3.0B+2.2%	$2.9B+0.7%	$3.0B+1.2%	$3.0B-5.9%	$2.9B-8.0%	$2.9B
Long-Term Debt	$2.5B+1.0%	$2.5B+0.3%	$2.5B+0.1%	$2.5B-2.1%	$2.5B-1.7%	$2.5B-10.5%	$2.5B-10.4%	$2.5B
Total Equity	$5.2B+9.9%	$5.0B-1.6%	$4.8B-2.2%	$4.6B-4.7%	$4.8B+2.6%	$5.1B-1.0%	$5.0B-6.6%	$4.8B
Retained Earnings	$3.6B+17.8%	$3.4B+19.9%	$3.2B+20.9%	$3.0B+22.5%	$3.0B+32.3%	$2.8B+44.8%	$2.7B+32.9%	$2.5B

HOLX Cash Flow Statement

HOLX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$1.1B	$1.1B-17.7%	$1.3B+22.3%	$1.1B-50.5%	$2.1B-8.8%	$2.3B+159.9%	$896.6M+38.0%	$649.5M-11.4%	$732.9M+8730.1%	$8.3M-99.0%	$798.2M+0.2%	$796.8M+56.7%	$508.4M+3.0%	$493.8M+33.4%	$370.2M-18.8%	$456.0M
Depreciation & Amortization	N/A	$299.8M-3.0%	$309.0M-4.5%	$323.4M-24.8%	$430.1M+5.7%	$406.9M+8.2%	$376.0M-18.8%	$463.1M-3.6%	$480.3M+6.9%	$449.2M-3.5%	$465.4M-5.3%	$491.4M-6.1%	$523.2M+1.4%	$516.0M+49.2%	$345.8M+13.5%	$304.7M
Stock-Based Compensation	N/A	$84.3M+2.4%	$82.3M+3.4%	$79.6M+19.3%	$66.7M+2.6%	$65.0M-22.0%	$83.3M+34.4%	$62.0M-4.6%	$65.0M-4.7%	$68.2M+4.3%	$65.4M+10.3%	$59.3M+18.6%	$50.0M-4.4%	$52.3M+28.8%	$40.6M+14.5%	$35.5M
Capital Expenditures	$103.6M	$58.8M-18.8%	$72.4M-21.1%	$91.8M+30.0%	$70.6M-40.3%	$118.3M+20.3%	$98.3M+72.5%	$57.0M-2.4%	$58.4M+1.0%	$57.8M+22.2%	$47.3M-1.7%	$48.1M+8.6%	$44.3M-9.6%	$49.0M+48.0%	$33.1M+19.1%	$27.8M
Free Cash Flow	$994.1M	$998.3M-17.7%	$1.2B+26.4%	$959.4M-53.3%	$2.1B-7.1%	$2.2B+177.1%	$798.3M+34.7%	$592.5M-12.2%	$674.5M+1462.6%	-$49.5M-106.6%	$750.9M+0.3%	$748.7M+61.3%	$464.1M+4.3%	$444.8M+31.9%	$337.1M-21.3%	$428.2M
Investing Cash Flow	-$472.8M	-$482.7M+38.2%	-$781.0M-413.5%	-$152.1M+26.3%	-$206.3M+84.5%	-$1.3B-839.0%	-$141.6M+49.6%	-$280.7M-43.8%	-$195.2M-168.3%	$285.8M+517.8%	-$68.4M+20.6%	-$86.1M-28.5%	-$67.0M-456.4%	$18.8M+100.5%	-$3.9B-1344.5%	-$266.6M
Financing Cash Flow	-$250.9M	-$777.2M+29.9%	-$1.1B-129.4%	-$483.2M+36.1%	-$756.0M-42.7%	-$529.8M+19.7%	-$659.9M-52.9%	-$431.5M-6.6%	-$404.8M-30.9%	-$309.2M+53.9%	-$670.7M+29.2%	-$947.4M-80.4%	-$525.1M-111.1%	-$248.8M-107.5%	$3.3B+43268.5%	$7.7M
Share Buybacks	$235.6M	$752.9M-9.8%	$835.1M+75.9%	$474.8M-12.4%	$542.1M+32.3%	$409.8M-37.3%	$653.6M+226.6%	$200.1M-27.4%	$275.8M+37.8%	$200.1M-20.0%	$250.0M	$0	$0	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	$229.9M+21.4%	$355.1M-3.2%	$343.3M-15.4%	$169.4M-42.1%	$189.3M-14.0%	$367.0M+10.3%	$405.8M+96.7%	$292.4M
Depreciation & Amortization	$69.6M-5.9%	$79.5M+6.6%	$70.2M-2.9%	$76.2M+3.4%	$74.0M-16.3%	$74.6M-8.1%	$72.3M-10.5%	$73.7M
Stock-Based Compensation	$26.9M-10.6%	N/A	$13.5M-7.5%	$28.4M+10.1%	$30.1M+4.9%	N/A	$14.6M-37.1%	$25.8M
Capital Expenditures	$14.7M-12.5%	$13.7M-16.5%	$34.9M+2.9%	$40.3M+43.9%	$16.8M-26.0%	$16.4M-55.1%	$33.9M+5.6%	$28.0M
Free Cash Flow	$215.2M+24.8%	$341.4M-2.6%	$308.4M-17.1%	$129.1M-51.2%	$172.5M-12.6%	$350.6M+18.3%	$371.9M+113.5%	$264.4M
Investing Cash Flow	-$12.1M+45.0%	-$132.1M+77.8%	-$4.3M+89.9%	-$324.3M-742.3%	-$22.0M+78.9%	-$595.7M-1439.3%	-$42.6M-159.8%	-$38.5M
Financing Cash Flow	-$10.7M+98.0%	$1.6M+102.8%	-$40.1M+61.4%	-$201.7M-4702.4%	-$537.0M+43.1%	-$56.8M+48.2%	-$103.8M-109.7%	-$4.2M
Share Buybacks	$0-100.0%	$0-100.0%	$35.6M-64.4%	$200.0M	$517.3M-23.6%	$58.3M-48.7%	$100.0M+100.0%	$0

Not reported in any period shown, so not listed: Dividends Paid.

HOLX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HOLX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	51.6%-3.6pp	55.3%+3.9pp	51.4%-10.2pp	61.6%-5.8pp	67.4%+8.4pp	59.0%+24.2pp	34.8%-18.0pp	52.7%-0.3pp	53.0%-2.2pp	55.2%+2.2pp	53.0%+3.7pp	49.2%+2.6pp	46.6%-3.1pp	49.7%-21.2pp	70.9%
Operating Margin	17.4%-4.5pp	21.9%+5.3pp	16.6%-17.1pp	33.7%-10.3pp	44.0%+14.8pp	29.3%+32.9pp	-3.7%+3.7pp	-7.4%-52.2pp	44.8%+25.4pp	19.4%+2.6pp	16.8%+5.8pp	11.1%+47.4pp	-36.4%-42.0pp	5.7%-15.3pp	20.9%
Net Margin	13.8%-5.8pp	19.6%+8.3pp	11.3%-15.5pp	26.8%-6.5pp	33.2%+3.7pp	29.5%+35.6pp	-6.0%-2.6pp	-3.5%-28.2pp	24.7%+13.0pp	11.7%+6.8pp	4.9%+4.2pp	0.7%+47.7pp	-47.1%-43.4pp	-3.7%-12.5pp	8.8%
Return on Equity	11.2%-4.2pp	15.4%+6.3pp	9.1%-17.6pp	26.7%-17.7pp	44.4%+3.1pp	41.2%+50.8pp	-9.6%-5.0pp	-4.6%-31.7pp	27.1%+11.7pp	15.4%+9.1pp	6.3%+5.5pp	0.8%+61.2pp	-60.4%-57.9pp	-2.5%-7.8pp	5.3%
Return on Assets	6.3%-2.3pp	8.6%+3.6pp	5.0%-9.4pp	14.3%-6.6pp	21.0%+5.5pp	15.5%+18.7pp	-3.2%-1.6pp	-1.5%-11.0pp	9.5%+5.0pp	4.5%+2.8pp	1.7%+1.5pp	0.2%+13.2pp	-13.0%-12.3pp	-0.7%-3.3pp	2.6%
Current Ratio	3.75+0.1x	3.69+0.2x	3.47-0.7x	4.12+1.7x	2.39+0.6x	1.79+0.1x	1.68+0.4x	1.23+0.4x	0.79-0.7x	1.47+0.1x	1.34-1.2x	2.53+1.0x	1.49-0.9x	2.36-0.3x	2.64
Debt-to-Equity	0.500.0x	0.490.0x	0.50-0.1x	0.58-0.1x	0.64-0.4x	1.00-0.3x	1.32+0.2x	1.11+0.3x	0.78-0.6x	1.42-0.1x	1.55-0.5x	2.01-0.2x	2.19+0.5x	1.68+1.2x	0.51
Asset Turnover	0.450.0x	0.440.0x	0.44-0.1x	0.54-0.1x	0.63+0.1x	0.520.0x	0.52+0.1x	0.45+0.1x	0.380.0x	0.390.0x	0.35+0.1x	0.300.0x	0.28+0.1x	0.19-0.1x	0.30
FCF Margin	24.3%-5.7pp	30.1%+6.3pp	23.8%-18.5pp	42.3%+3.0pp	39.3%+18.1pp	21.1%+3.5pp	17.6%-3.4pp	21.0%+22.6pp	-1.6%-28.1pp	26.5%-1.2pp	27.7%+9.3pp	18.3%+0.5pp	17.8%+1.0pp	16.8%-7.1pp	23.9%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q
Gross Margin	56.0%-0.9pp	55.6%-0.9pp	56.3%+0.9pp	37.5%-15.8pp	56.8%+0.8pp	56.5%+19.1pp	55.4%-1.7pp	53.3%
Operating Margin	22.6%+0.1pp	22.6%-0.7pp	24.9%+0.8pp	-0.7%-21.4pp	22.5%+2.9pp	23.3%+23.1pp	24.1%-2.4pp	20.7%
Net Margin	17.1%-2.6pp	17.8%-0.2pp	19.0%-0.2pp	-1.7%-18.4pp	19.7%-4.7pp	18.1%+22.2pp	19.2%-2.1pp	16.7%
Return on Equity	3.4%-0.8pp	3.7%+0.2pp	4.0%+0.1pp	-0.4%-3.9pp	4.2%-1.1pp	3.5%+4.3pp	3.9%-0.2pp	3.5%
Return on Assets	1.9%-0.3pp	2.1%+0.1pp	2.2%0.0pp	-0.2%-2.1pp	2.3%-0.6pp	1.9%+2.4pp	2.2%-0.1pp	1.9%
Current Ratio	4.04+0.6x	3.75+0.1x	3.55-0.4x	3.24-0.7x	3.49-0.4x	3.69-0.7x	3.99-0.4x	3.97
Debt-to-Equity	0.480.0x	0.500.0x	0.520.0x	0.530.0x	0.520.0x	0.49-0.1x	0.510.0x	0.52
Asset Turnover	0.110.0x	0.120.0x	0.120.0x	0.120.0x	0.120.0x	0.110.0x	0.110.0x	0.12
FCF Margin	20.5%+3.7pp	32.5%-3.0pp	30.1%-6.7pp	12.8%-13.1pp	16.9%-2.6pp	35.5%+5.4pp	36.8%+19.8pp	26.0%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Hologic Inc HOLX	FY2025	$4.1B	$565.7M	13.8%	$17.0B	69/100
The Cooper Companies, Inc. COO	FY2025	$4.1B	$374.9M	9.2%	$10.4B	59/100
Solventum Corporation SOLV	FY2025	$8.3B	$1.6B	18.7%	$14.7B	50/100
Baxter International Inc. BAX	FY2025	$11.2B	-$957.0M	-8.5%	$12.9B	36/100
West Pharmaceutical Services, Inc. WST	FY2025	$3.1B	$493.7M	16.1%	$26.2B	76/100
ResMed Inc. RMD	FY2026	$5.7B	$1.5B	26.9%	$33.1B	87/100

Where Hologic Inc Ranks

Frequently Asked Questions

What is Hologic Inc's annual revenue?

Hologic Inc (HOLX) reported $4.1B in total revenue for fiscal year 2025. This represents a 1.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Hologic Inc's revenue growing?

Hologic Inc (HOLX) revenue grew by 1.7% year-over-year, from $4.0B to $4.1B in fiscal year 2025.

Is Hologic Inc profitable?

Yes, Hologic Inc (HOLX) reported a net income of $565.7M in fiscal year 2025, with a net profit margin of 13.8%.

What is Hologic Inc's EBITDA?

Hologic Inc (HOLX) had EBITDA of $1.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Hologic Inc have?

As of fiscal year 2025, Hologic Inc (HOLX) had $2.0B in cash and equivalents against $2.5B in long-term debt.

What is Hologic Inc's gross margin?

Hologic Inc (HOLX) had a gross margin of 51.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Hologic Inc's operating margin?

Hologic Inc (HOLX) had an operating margin of 17.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Hologic Inc's net profit margin?

Hologic Inc (HOLX) had a net profit margin of 13.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Hologic Inc's return on equity (ROE)?

Hologic Inc (HOLX) has a return on equity of 11.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Hologic Inc's free cash flow?

Hologic Inc (HOLX) generated $998.3M in free cash flow during fiscal year 2025. This represents a -17.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Hologic Inc's operating cash flow?

Hologic Inc (HOLX) generated $1.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Hologic Inc's total assets?

Hologic Inc (HOLX) had $9.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Hologic Inc's capital expenditures?

Hologic Inc (HOLX) invested $58.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Hologic Inc spend on research and development?

Hologic Inc (HOLX) invested $248.2M in research and development during fiscal year 2025.

Does Hologic Inc buy back shares?

Yes, Hologic Inc (HOLX) spent $752.9M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Hologic Inc have outstanding?

Hologic Inc (HOLX) had 223M shares outstanding as of fiscal year 2025.

What is Hologic Inc's current ratio?

Hologic Inc (HOLX) had a current ratio of 3.75 as of fiscal year 2025, which is generally considered healthy.

What is Hologic Inc's debt-to-equity ratio?

Hologic Inc (HOLX) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Hologic Inc's return on assets (ROA)?

Hologic Inc (HOLX) had a return on assets of 6.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Hologic Inc's Altman Z-Score?

Hologic Inc (HOLX) has an Altman Z-Score of 4.17, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Hologic Inc's Piotroski F-Score?

Hologic Inc (HOLX) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Hologic Inc's earnings high quality?

Hologic Inc (HOLX) has an earnings quality ratio of 1.87x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Hologic Inc cover its interest payments?

Hologic Inc (HOLX) has an interest coverage ratio of 6.10x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Hologic Inc?

Hologic Inc (HOLX) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.